Clinical efficacy of cytarabine + aclarubicin + recombinant human granulocyte colony-stimulating factor regimen combined with decitabine for adult acute myeloid leukemia

References

• Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, et al. 2017. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 130(6):732–741. doi: https://doi.org/10.1182/blood-2017-04-779447
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Rowe JM, Radich J, Dick JE. 2001. Acute myeloid leukemia. Hematology. 2001(1):62–86. doi: https://doi.org/10.1182/asheducation-2001.1.62
   Google Scholar
• Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, Quaranta D, Tonali PA, Barone C. 2011. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol. 67(5):1179–1187. doi: https://doi.org/10.1007/s00280-010-1466-y
   Google Scholar
• Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Jeong Kim E, et al. 2017. NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw. 15(7):883–893. doi: https://doi.org/10.6004/jnccn.2017.0117
   PubMed Web of Science ®Google Scholar
• Bird A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1):6–21. doi: https://doi.org/10.1101/gad.947102
   PubMed Web of Science ®Google Scholar
• Dou LP, Jing Y, Wang QS, Mei JH, Yu L. 2013. Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21(3):662–666.
   Google Scholar
• Iris S, Matthew B, Veronika N, Chao W, Sara R, Nancy K, Fang-Yong L, Ehrenkranz RA, Rinder HM, Vineet B. 2013. Neutrophil CD64 with hematologic criteria for diagnosis of neonatal sepsis. Am J Perinatol. 31(1):021–030. doi: https://doi.org/10.1055/s-0033-1334453
   Google Scholar
• Momparler RL, Cote S, Momparler LF, Idaghdour Y. 2017. Inhibition of DNA and histone methylation by 5-aza-2'-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells. Front Oncol. 7:19. doi: https://doi.org/10.3389/fonc.2017.00019
   Google Scholar
• Nair CK, Kumar M, Odayoth SM. 2013. Pleural effusion during acute myeloid leukemia induction chemotherapy: a perplexing case. J Cancer Res Ther. 9(2):290–291. doi: https://doi.org/10.4103/0973-1482.113390
   Google Scholar
• Niitsu N, Hayashi Y, Sugita K, Honma Y. 2015. Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3. Br J Haematol. 112(2):315–326. doi: https://doi.org/10.1046/j.1365-2141.2001.02523.x
   Google Scholar
• Obara M, Ara T, Shima K, Yasumoto A, Nakata M, Ota S, Imai K, Hirano T, Kiyama Y, Ogasawara M. 2013. Aclarubicin, low-dose cytarabine combined with G-CSF (CAG) regimen for patients previously treated or ineligible for intensive chemotherapy with acute myeloid leukemia and myelodysplastic syndrom: a single center experience. Blood. 122:1241–1241. doi: https://doi.org/10.1182/blood.V122.21.1241.1241
   Google Scholar
• Qiao X, Yin F, Ji Y, Li Y, Yan P, Lai J. 2017. 5-Aza-2'-deoxycytidine in the medial prefrontal cortex regulates alcohol-related behavior and Ntf3-TrkC expression in rats. PLoS One. 12(6):e0179469. doi: https://doi.org/10.1371/journal.pone.0179469
   PubMed Web of Science ®Google Scholar
• Ramos MP, Wijetunga NA, McLellan AS, Suzuki M, Greally JM. 2015. DNA demethylation by 5-aza-2'-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences. Epigenetics Chromatin. 8:11. doi: https://doi.org/10.1186/s13072-015-0004-x
   Google Scholar
• Rastogi N. 2018. Genetics of acute myeloid leukemia - a paradigm shift. Indian Pediatr. 55(6):465–468. doi: https://doi.org/10.1007/s13312-018-1334-0
   Google Scholar
• Robertson M, Schrey A, Shayter A, Moss CJ, Richards C. 2017. Genetic and epigenetic variation in Spartina alterniflora following the Deepwater Horizon oil spill. Evol Appl. 10(8):792–801. doi: https://doi.org/10.1111/eva.12482
   PubMed Web of Science ®Google Scholar
• Sayad A, Hajifathali A, Hamidieh AA, Roshandel E, Taheri M. 2017. HOTAIR long noncoding RNA is not a biomarker for acute myeloid leukemia (AML) in Iranian patients. Asian Pac J Cancer Prev. 18(6):1581–1584.
   PubMedGoogle Scholar
• Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM. 2018. Effects of 5-aza-2'-deoxycytidine (decitabine) on gene expression. Drug Metab Rev. 50(2):193–207. doi: https://doi.org/10.1080/03602532.2018.1437446
   PubMed Web of Science ®Google Scholar
• Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, et al. 2018. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 131(4):387–396. doi: https://doi.org/10.1182/blood-2017-06-789800
   PubMed Web of Science ®Google Scholar
• Stich M, Ganss L, Puschhof J, Prigge ES, Reuschenbach M, Guiterrez A, Vinokurova S, Doeberitz MVK. 2017. 5-Aza-2′-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells. Oncotarget. 8(32):52104–52117. doi: https://doi.org/10.18632/oncotarget.10631
   PubMedGoogle Scholar
• Tabayashi T, Takahashi Y, Kimura Y, Tomikawa T, Sagawa M, Anan T, Watanabe R, Tokuhira M, Mori S, Kizaki M. 2014. P1-21-1efficacy of low-dose cytarabine-based regimen(CAG)followed by azacitidine for elderly patients with MDS/AML. Ann Oncol. 25(suppl 5):v84–v84. doi: https://doi.org/10.1093/annonc/mdu436.42
   Google Scholar
• Wang J, Jiang B, Jiang Q, Lu J, Zhu HH, Yang SM, Zhao T, Wen L, Bao L, Huang XJ, et al. 2016. Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen. Zhonghua Xue Ye Xue Za Zhi. 37(3):194–200.
   Google Scholar
• Weinberg OK, Sohani AR, Bhargava P, Nardi V. 2017. Diagnostic work-up of acute myeloid leukemia. Am J Hematol. 92(3):317–321. doi: https://doi.org/10.1002/ajh.24648
   Google Scholar
• Xie MY, Yang Y, Liu P, Luo Y, Tang SB. 2019. 5-Aza-2'-deoxycytidine in the regulation of antioxidant enzymes in retinal endothelial cells and rat diabetic retina. Int J Ophthalmol. 12(1):1–7.
   Web of Science ®Google Scholar
• Zheng C, Cai X, Wu S, Liu Z, Shi Y, Zhou W. 2014. Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia. Pak J Med Sci. 30(6):1270–1272.
   Web of Science ®Google Scholar